EGFR and non-small cell lung carcinoma: The Japan Lung Cancer Society guidelines recommend that all patients diagnosed with NSCLC should be tested for actionable biomarkers, including EGFR mutations, anaplastic lymphoma kinase rearrangements/fusion, and programmed cell death (ligand) 1 (PD-[L]1) expression [5,6].